Sonnet BioTherapeutics Holdings, Inc. (SONN): Utang marang Ekuitas

Logo korporat perusahaan Sonnet BioTherapeutics Holdings (SONN)

Sonnet BioTherapeutics develops innovative tumor-fighting methods utilizing the FHAB platform for targeted drug delivery. This chart of the share price on GURU.Markets shows that the total debt-to-equity ratio is 0.00. The high value of the product will provide the company with market influence, while the localization of development in the US completely eliminates geopolitical threats and trade barriers.

SONN: Rasio Total Utang marang Ekuitas Sonnet BioTherapeutics Holdings Inc. 04.07.2022 - 13.12.2025

Rincian metrik komprehensif lan analitis Sonnet BioTherapeutics Holdings (SONN)

- rega lan prakiraan konsensus rega:
Bagan rega Sonnet BioTherapeutics Holdings, Inc.|SONN - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Sonnet BioTherapeutics|SONN - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Sonnet BioTherapeutics|SONN - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku sonnetbio.com|SONN - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Sonnet BioTherapeutics|SONN - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Sonnet BioTherapeutics Holdings, Inc.|SONN - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Sonnet BioTherapeutics|SONN - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Sonnet BioTherapeutics|Indikator likuiditas cepet sonnetbio.com
- informasi bathi lan kelipatan valuasi:
SONN - Bathi pungkasan
Analisis fundamental perusahaan:Sonnet BioTherapeutics, SONN
Barang utama Sonnet BioTherapeutics Holdings, Inc.

This metric is calculated as the ratio of total liabilities to net asset value, measuring the business's reliance on debt financing relative to its equity. Analyzing the D/E ratio (total debt-to-equity) allows for an assessment of the financial stability of Sonnet BioTherapeutics (SONN) as it implements a capital-intensive strategy to develop targeted cancer immunotherapy based on the FHAB platform.

Pesaing Sonnet BioTherapeutics (SONN)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Immunocore Holdings IMCR|Utang marang Ekuitas Janux Pharma (JANX)|Arcus Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal ZYME (Zymeworks Inc.)|TNGX - Rasio Total Utang marang Ekuitas|IOVA - Utang marang Ekuitas|Utang marang Modal Immatics NV|Xencor Corp (XNCR) - Utang marang Ekuitas|CMPX (Compass Therapeutics Corp) - Utang marang Ekuitas|Utang marang Ekuitas Replimune Group, Inc.|Utang marang Modal lyell.com LYEL|Total Utang marang Modal IPHA|pyxisoncology.com (PYXS) - Rasio Utang marang Modal|Compugen - Rasio Total Utang marang Ekuitas|IO Biotech Inc. (IOBT) - Utang marang Modal|STRO: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi INKT (minktherapeutics.com)|HOWL: Total Utang marang Modal|IMMX - Koefisien Total Utang marang Modal|Utang marang Ekuitas ALX Oncology Holdings|Rasio Total Utang marang Ekuitas cuebiopharma.com (CUE)|Utang marang Ekuitas PDS Biotechnology (PDSB)|Rasio Total Utang marang Ekuitas MAIABiotech.com MAIA|Liminatus Pharma LLC - Rasio Total Utang marang Ekuitas|Total Utang marang Modal LAVA Therapeutics NV LVTX|NXTC - Utang marang Ekuitas|LPTX (Leap Therapeutics, Inc.) - Rasio Utang marang Ekuitas|intensitytherapeutics.com (INTS) - Utang marang Ekuitas|Utang marang Modal Sensei Biotherapeutics, Inc. (SNSE)|Rasio Total Utang marang Ekuitas TOVX|GRTS - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas KA (Kineta Bio)|Utang Agregat marang Modal NEXI|Total Utang marang Modal TSBX (Turnstone Biologics Corp.)|Rasio Kabeh Utang marang Dana Pribadi VCNX|Harpoon Therapeutics, Inc. - Total Utang marang Modal